Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC176 in mCRPC
NCT05241613Phase 1Terminated
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Mar 2022
- Primary completion
- Mar 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AC0176 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Accutar Biotechnology, Inc. Primary endpoints: Incidence of dose limiting toxicities at 28 days, Adverse events / Serious adverse events at 24 months and 3 more. Started Mar 2022; status: terminated.
02
Drugs
AC0176
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05241613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241613.